<DOC>
	<DOC>NCT01313858</DOC>
	<brief_summary>This is a study to assess the use of golimumab (Simponi速) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study objective is to evaluate the clinical safety of golimumab (Simponi速) under real-life, clinical practice conditions as assessed by the incidence and type of (serious) adverse events and changes in clinical status of participants as assessed by clinical parameters.</brief_summary>
	<brief_title>A Study to Investigate the Use of Golimumab (Simponi速) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Has rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis and treatment with Simponi速 by autoinjector device is to be initiated for the first time No specific exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>